This post was originally published on this site ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to exploratory analysis on the data of the FORWARD I Phase 3 trial (NCT02631876). Previous analysis of the…
Conditions
Conditions
Jevtana Delays Disease Progression, Prolongs Survival in Men with mCRPC, Phase 4 Trial Shows
This post was originally published on this site The chemotherapy agent Jevtana (cabazitaxel) is better than a second course of androgen receptor inhibitors at delaying disease progression and prolonging survival among men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 4 trial shows. All of the participants had seen their disease progress while previously receiving…
Opdivo-Yervoy Combo Prolongs Survival in Patients with Advanced NSCLC, Phase 3 Study Shows
This post was originally published on this site A combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induces significant survival benefits in people with advanced non-small cell lung cancer (NSCLC), compared to chemotherapy alone, data from a Phase 3 trial show. These findings suggest first-line Opdivo-Yervoy combo as the first immunotherapy to induce better overall…
Consolidation Radiotherapy Important After Treatment for Early Hodgkin’s Lymphoma, Clinical Study Shows
This post was originally published on this site Radiotherapy following chemotherapy reduces the risk of cancer progression in people with early-stage favorable Hodgkin’s lymphoma, regardless of an individual’s response to chemotherapy, results of a Phase 3 study show. These findings support the importance of consolidation radiotherapy — which appears to prevent potential cancer relapse or…
NDX-1017 Phase 1 Trial Complete, Results Will Be Presented at CTAD Conference, Athira Says
This post was originally published on this site Athira Pharma has completed the Phase 1 trial testing NDX-1017, its lead therapeutic candidate for Alzheimer’s disease, and will present the results at the 12th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference in December. Preliminary results showed the therapy, which has the potential to be regenerative and…
Terranea Resort Turns Pink for National Breast Cancer Awareness Month
This post was originally published on this site In observance of National Breast Cancer Awareness Month, the Los Angeles oceanfront resort Terranea will again “turn pink” to benefit breast cancer organizations. Throughout October, Terranea will — for the fourth year — reprise its “Terranea Turns Pink” initiative, which donates a portion of proceeds from golf…
Keytruda Approved in China as First-Line Lung Cancer Treatment
This post was originally published on this site The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) announced. The approval covers patients who have tumors with at least 1% of cells producing the PD-L1 protein,…
Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma
This post was originally published on this site IASO Biotherapeutics and Innovent Biologics are preparing the launch of a Phase 1b/2 clinical trial in China to evaluate the companies’ novel CAR T-cell product, CT103A, in people with relapsed or refractory multiple myeloma. The announcement comes after the therapy was granted Investigational New Drug status by…
Navicixizumab Earns FDA Fast Track Designation for Heavily Pretreated Ovarian Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast track designation is given to investigational compounds that show considerable potential in treating serious conditions for which available…
Zejula Granted FDA’s Breakthrough Therapy Status for Treating Metastatic Castration-resistant Prostate Cancer
This post was originally published on this site The oral ovarian cancer treatment Zejula (niraparib) has been given Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who carry BRCA mutations and have been previously treated with certain therapies, namely taxane chemotherapy and androgen-receptor…
Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment
This post was originally published on this site The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, has announced. This is in addition to a prior fast track designation granted in 2017 for the…
$35M Gift from Benioffs to Support Prostate Cancer Research Initiative at UCSF
This post was originally published on this site A $35 million gift from Marc and Lynne Benioff will support a new initiative at the University of California, San Francisco (UCSF) aimed at finding personalized treatments for prostate cancer. “With this gift, we are honoring the memory of Marc’s father and all of those who have…